CTNNA1 Familial Expansion Study

Breast Cancer Clinical Trial

— CAFÉ  

Official title:

CTNNA1 Familial Expansion (CAFÉ) Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05126290
• Other study ID #: UPCC 21220
• Secondary ID: 844070
• Status: Recruiting
• Start date: March 16, 2021
• Est. completion date: January 1, 2026

Study information

• Verified date: February 2024
• Source: Abramson Cancer Center at Penn Medicine
• Contact: Bryson W Katona, MD, PhD
• Phone: 215-349-8222
• Email: cafestudy[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Description:

The CAFÉ Study aims to determine the degree to which loss-of-function variants in the CTNNA1 gene are associated with hereditary cancers, including gastric cancer, breast cancer, as well as other cancers that may be associated with this gene. By obtaining personal and family history information from individuals who carry a CTNNA1 loss-of-function variant and their family members, this study will aim to better define CTNNA1 associated cancer risks and determine whether there is a genotype/phenotype correlation for CTNNA1 loss-of-function variants. This information will be important for the future cancer risk management of individuals who carry a CTNNA1 loss-of-function variant.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age and older

• Participants must be carrier, or a first degree relative of a carrier, of a CTNNA1 loss-of-function variant defined as: a variant predicted to lead to protein truncation (nonsense and frameshift variants), a large deletion of one or more exons, or a consensus splice site variant predicted to disrupt splicing in CTNNA1. CTNNA1 loss-of-function variants do not need to be classified as pathogenic or likely pathogenic to be included.

• Participants must be able to understand and read English

• Participants must be able to provide informed verbal or written consent

Exclusion Criteria:

• Less than 18 years of age

• Individuals who do not carry a CTNNA1 loss-of-function variant and are not a first degree relative of a CTNNA1 loss-of-function variant carrier.

• Individuals who cannot speak and read English

• Major psychiatric illness or cognitive impairment that in the judgement of the study investigators or study staff would preclude study participation

• Unable to comply with the study procedures as determined by the study investigators or study staff

Related Conditions & MeSH terms

• Breast Cancer
• Cancer Gene Mutation
• Gastric Cancer
• Stomach Neoplasms

Intervention

Other:
• Collection of personal and family history from CAFÉ Study participants
Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

References & Publications (1)

Clark DF, Michalski ST, Tondon R, Nehoray B, Ebrahimzadeh J, Hughes SK, Soper ER, Domchek SM, Rustgi AK, Pineda-Alvarez D, Anderson MJ, Katona BW. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet Med. 2020 May;22(5):840-846. doi: 10.1038/s41436-020-0753-1. Epub 2020 Feb 13. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of cancer amongst carriers of CTNNA1 loss-of-function variants	After collecting personal and family cancer history from enrolled participants, family pedigrees will be utilized to calculate cancer risk estimates for for CTNNA1 loss-of-function variant carriers including gastric cancer risk, breast cancer risk, as well as risk of other cancers currently not known to be associated with CTNNA1 variants gene.	Through study completion, which will average 1 year
Primary	Number of CTNNA1 genotypes associated with a cancer phenotype	Using collected family pedigrees from enrolled participants, we will correlate estimated cancer risk for CTNNA1 loss-of-function variant carriers with their CTNNA1 genotype, to determine if there is a significant genotype-phenotype correlation observed.	Through study completion, which will average 1 year

External Links

•   Study website